New Appointment to the FDA's Office of Public Health and Science
New director appointed to the Office for Human Research Protections (OHRP).
HHS Assistant Secretary for Health Joxel García, M.D., M.B.A., today announced the appointment of Jerry A. Menikoff, M.D., J.D, as the director of the Office for Human Research Protections (OHRP), part of the Office of Public Health and Science, in the Office of the Secretary.
Prior to joining OHRP, Dr. Menikoff served as the director of the Office of Human Subjects Research and a bioethicist, both at the National Institutes of Health. He has written extensively on research and human subject protections, including several books and numerous journal articles, over the past fifteen years.
Previous to his NIH appointments, Dr. Menikoff served for nine years as the chair of the human subjects committee and the hospital ethics committee at the University of Kansas Medical Center. His educational background includes an M.D. from Washington University and law and public policy degrees from Harvard. In addition, Dr. Menikoff has held academic positions in schools of law at the University of Akron, the University of Chicago, and Hofstra University, Hempstead, NY. He is on leave from the position of associate professor of law, ethics and medicine at the University of Kansas.
Dr. Ivor Pritchard, who had served as OHRP’s acting director since September 2007, will return to his position as senior advisor to the OHRP director.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
